Citations

Clear

108 citation(s) found for "Sheth, S".

History and Evolution of Yttrium-90 Radioembolization for Hepatocellular Carcinoma
Saini, Aman , Wallace, Alex, Alzubaidi, Sadeer , Knuttinen, M. Grace , Naidu, Sailendra , Sheth, Rahul A. , Albadawi, Hassan , Öklü, Rahmi , Oklu, Rahmi

Mayo Clinic

Journal of Clinical Medicine | January 10, 2019 | Volume: 8 | Issue: 1 | Pages: 55

10.3390/jcm8010055 | PMID 30621040 Get It

Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and affects millions worldwide. Due to the lack of effective systemic therapies for HCC, researchers have been investigating the use of locoregional tumor control with Yttrium-90 (Y90) radioembolization since the 1960s. Following the development of glass and resin Y90 microspheres in the early 1990s, Y90 radioembolization has been shown to be a safe and efficacious treatment for patients with HCC across Barcelona Clinic Liver Cancer (BCLC) stages. By demonstrating durable local control, good long term outcomes, and equivalent if not superior tumor responses and tolerability when compared to alternative therapies including transarterial chemoembolization (TACE) and sorafenib, Y90 radioembolization is being increasingly used in HCC treatment. More recently, investigations into variations in Y90 radioembolization technique including radiation segmentectomy and radiation lobectomy have further expanded its clinical utility. Here, we discuss the history and evolution of Y90 use in HCC. We outline key clinical trials that have established the safety and efficacy of Y90 radioembolization, and also summarize trials comparing its efficacy to existing HCC treatments. We conclude by reviewing the techniques of radiation segmentectomy and lobectomy, and by discussing dosimetry.
Radiogenomics and Radiomics in Liver Cancers
Saini, Aman , Breen, Ilana, Naidu, Sailendra , Knuttinen, M. Grace , Alzubaidi, Sadeer , Sheth, Rahul A. , Albadawi, Hassan , Kuo, Malia, Öklü, Rahmi , Pershad, Yash , Oklu, Rahmi

Mayo Clinic

Diagnostics | December 27, 2018 | Volume: 9 | Issue: 1 | Pages: 4

10.3390/diagnostics9010004 | PMID 30591628 Get It

Radiogenomics is a computational discipline that identifies correlations between cross-sectional imaging features and tissue-based molecular data. These imaging phenotypic correlations can then potentially be used to longitudinally and non-invasively predict a tumor’s molecular profile. A different, but related field termed radiomics examines the extraction of quantitative data from imaging data and the subsequent combination of these data with clinical information in an attempt to provide prognostic information and guide clinical decision making. Together, these fields represent the evolution of biomedical imaging from a descriptive, qualitative specialty to a predictive, quantitative discipline. It is anticipated that radiomics and radiogenomics will not only identify pathologic processes, but also unveil their underlying pathophysiological mechanisms through clinical imaging alone. Here, we review recent studies on radiogenomics and radiomics in liver cancers, including hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and metastases to the liver.
Irreversible Electroporation in Liver Cancers and Whole Organ Engineering
Saini, Aman , Breen, Ilana, Alzubaidi, Sadeer , Sheth, Rahul A. , Naidu, Sailendra , Knuttinen, M. Grace , Albadawi, Hassan , Öklü, Rahmi , Pershad, Yash , Oklu, Rahmi

Mayo Clinic

Journal of Clinical Medicine | December 26, 2018 | Volume: 8 | Issue: 1 | Pages: 22

10.3390/jcm8010022 | PMID 30585195 Get It

Liver cancers contribute significantly to cancer-related mortality worldwide and liver transplants remain the cornerstone of curative treatment for select, early-stage patients. Unfortunately, because of a mismatch between demand and supply of donor organs, liver cancer patients must often wait extended periods of time prior to transplant. A variety of local therapies including surgical resection, transarterial chemoembolization, and thermal ablative methods exist in order to bridge to transplant. In recent years, a number of studies have examined the role of irreversible electroporation (IRE) as a non-thermal local ablative method for liver tumors, particularly for those adjacent to critical structures such as the vasculature, gall bladder, or bile duct. In addition to proving its utility as a local treatment modality, IRE has also demonstrated promise as a technique for donor organ decellularization in the context of whole-organ engineering. Through complete non-thermal removal of living cells, IRE allows for the creation of an acellular extra cellular matrix (ECM) scaffold that could theoretically be recellularized and implanted into a living host. Here, we comprehensively review studies investigating IRE, its role in liver cancer treatment, and its utility in whole organ engineering.
17p12 Influences Hematoma Volume and Outcome in Spontaneous Intracerebral Hemorrhage
Devan, William J., Radmanesh, Farid , Miyares, Laura , Poterba, Timothy , Hansen, Björn M. , Jiménez-Conde, Jordi , Elosúa, Roberto , Cuadrado‐Godia, Elisa , Soriano‐Tárraga, Carolina , Roquer, Jaume , Kourkoulis, Christina , Schwab, Kristin , Tirschwell, David , Brown, Devin L. , Silliman, Scott, Worrall, Bradford B. , Kidwell, Chelsea S., Montaner, Joan , Delgado, Pilar , Greenberg, Steven M. , Matouk, Charles, Woo, Daniel , Anderson, Christopher D. , Falcone, Guido J. , Montaner, Joan , Marini, Sandro , Norrving, Bo , Giralt‐Steinhauer, Eva , Ayres, Alison M. , Selim, Magdy H. , Meschia, James F. , Fernández‐Cadenas, Israel , Lindgren, Arne G. , Sheth, Kevin N. , Rosand, Jonathan M.

Mayo Clinic

Stroke | June 18, 2018 | Volume: 49 | Issue: 7 | Pages: 1618-1625

10.1161/strokeaha.117.020091 | PMID 29915124 Get It

Background and Purpose— Hematoma volume is an important determinant of clinical outcome in spontaneous intracerebral hemorrhage (ICH). We performed a genome-wide association study (GWAS) of hematoma volume with the aim of identifying novel biological pathways involved in the pathophysiology of primary brain injury in ICH. Methods— We conducted a 2-stage (discovery and replication) case-only genome-wide association study in patients with ICH of European ancestry. We utilized the admission head computed tomography to calculate hematoma volume via semiautomated computer-assisted technique. After quality control and imputation, 7 million genetic variants were available for association testing with ICH volume, which was performed separately in lobar and nonlobar ICH cases using linear regression. Signals with P <5×10 − 8 were pursued in replication and tested for association with admission Glasgow coma scale and 3-month post-ICH dichotomized (0–2 versus 3–6) modified Rankin Scale using ordinal and logistic regression, respectively. Results— The discovery phase included 394 ICH cases (228 lobar and 166 nonlobar) and identified 2 susceptibility loci: a genomic region on 22q13 encompassing PARVB (top single-nucleotide polymorphism rs9614326: β, 1.84; SE, 0.32; P =4.4×10 −8 ) for lobar ICH volume and an intergenic region overlying numerous copy number variants on 17p12 (top single-nucleotide polymorphism rs11655160: β, 0.95; SE, 0.17; P =4.3×10 −8 ) for nonlobar ICH volume. The replication included 240 ICH cases (71 lobar and 169 nonlobar) and corroborated the association for 17p12 ( P =0.04; meta-analysis P =2.5×10 −9 ; heterogeneity, P =0.16) but not for 22q13 ( P =0.49). In multivariable analysis, rs11655160 was also associated with lower admission Glasgow coma scale (odds ratio, 0.17; P =0.004) and increased risk of poor 3-month modified Rankin Scale (odds ratio, 1.94; P =0.045). Conclusions— We identified 17p12 as a novel susceptibility risk locus for hematoma volume, clinical severity, and functional outcome in nonlobar ICH. Replication in other ethnicities and follow-up translational studies are needed to elucidate the mechanism mediating the observed association.
Early Diagnosis and Treatment of Lennox-Gastaut Syndrome
Resnick, Trevor, Sheth, Raj D.

Mayo Clinic

Journal of Child Neurology | September 8, 2017 | Volume: 32 | Issue: 11 | Pages: 947-955

10.1177/0883073817714394 | PMID 28689466 Get It

Lennox-Gastaut syndrome (LGS) is a severe form of childhood-onset epilepsy associated with high morbidity and mortality. The peak period for manifestations of Lennox-Gastaut syndrome is between ages 3 and 5 years, a time of critical brain development and corresponding vulnerability to the electroclinical dysfunction arising from Lennox-Gastaut syndrome. Diagnosis is based on a triad of symptoms: multiple seizure types, cognitive impairment, and slow spike-and-wave pattern on electroencephalography. In practice, Lennox-Gastaut syndrome presentation is diverse, and there may be a delay between initial symptoms and emergence of the full triad of clinical features. Additionally, differential diagnosis is complicated by the resemblance of Lennox-Gastaut syndrome to other forms of epilepsy and by the need for varied diagnostic techniques requiring specific clinical skills. Because diagnosis is complex and early intervention may lead to improved outcomes, clinicians should consider treatment when Lennox-Gastaut syndrome symptoms are present, even in the absence of a formal diagnosis.
Brain‐responsive neurostimulation in patients with medically intractable mesial temporal lobe epilepsy
Geller, Eric B., Skarpaas, Tara L. , Barkley, Gregory L., Bazil, Carl W., Berg, Michael J. van den, Bergey, Gregory K. , Cash, Sydney S. , Cole, Andrew J. , Duckrow, Robert B., Eisenschenk, Stephan, Fessler, James, Fountain, Nathan B. , Goldman, Alicia, Gwinn, Ryder P. , Heck, Christianne, Herekar, Aamar, Hirsch, Lawrence J. , Jobst, Barbara C. , King‐Stephens, David , Labar, Douglas, Leiphart, James W., Marsh, W. Richard , Meador, Kimford J. , Mizrahi, Eli M., Murro, Anthony M., Nair, Dileep , Park, Yong D., Rutecki, Paul , Salanova, Vicenta , Sheth, Raj D. , Shields, Donald C. , Skidmore, Christopher , Spencer, David , Srinivasan, Shraddha, Tatum, William O. , Ness, Paul C. Van, Vossler, David G. , Wharen, Robert E. , Yoshor, Daniel , Zimmerman, Richard S. , Cicora, Kathy, Sun, Felice T., Morrell, Martha J. , Cole, Andrew J , Noe, Katherine H. , Gross, Robert E. , Goodman, Robert , Berg, Michael J., Edwards, Jonathan , Smith, Michael C. F. , Worrell, Gregory A. , Fountain, Nathan , Hirsch, Lawrence J , Meador, Kimford J , Jobst, Barbara , Nair, Dileep R , Skidmore, Christopher , Morrell, Martha J

Mayo Clinic

Epilepsia | April 11, 2017 | Volume: 58 | Issue: 6 | Pages: 994-1004

10.1111/epi.13740 | PMID 28398014 Get It

SummaryObjectiveEvaluate the seizure‐reduction response and safety of mesial temporal lobe (MTL) brain‐responsive stimulation in adults with medically intractable partial‐onset seizures of mesial temporal lobe origin.MethodsSubjects with mesial temporal lobe epilepsy (MTLE) were identified from prospective clinical trials of a brain‐responsive neurostimulator (RNS System, NeuroPace). The seizure reduction over years 2–6 postimplantation was calculated by assessing the seizure frequency compared to a preimplantation baseline. Safety was assessed based on reported adverse events.ResultsThere were 111 subjects with MTLE; 72% of subjects had bilateral MTL onsets and 28% had unilateral onsets. Subjects had one to four leads placed; only two leads could be connected to the device. Seventy‐six subjects had depth leads only, 29 had both depth and strip leads, and 6 had only strip leads. The mean follow‐up was 6.1 ± (standard deviation) 2.2 years. The median percent seizure reduction was 70% (last observation carried forward). Twenty‐nine percent of subjects experienced at least one seizure‐free period of 6 months or longer, and 15% experienced at least one seizure‐free period of 1 year or longer. There was no difference in seizure reduction in subjects with and without mesial temporal sclerosis (MTS), bilateral MTL onsets, prior resection, prior intracranial monitoring, and prior vagus nerve stimulation. In addition, seizure reduction was not dependent on the location of depth leads relative to the hippocampus. The most frequent serious device‐related adverse event was soft tissue implant‐site infection (overall rate, including events categorized as device‐related, uncertain, or not device‐related: 0.03 per implant year, which is not greater than with other neurostimulation devices).SignificanceBrain‐responsive stimulation represents a safe and effective treatment option for patients with medically intractable epilepsy, including patients with unilateral or bilateral MTLE who are not candidates for temporal lobectomy or who have failed a prior MTL resection.
Brain‐responsive neurostimulation in patients with medically intractable seizures arising from eloquent and other neocortical areas
Jobst, Barbara C. , Kapur, Ritu, Barkley, Gregory L., Bazil, Carl W., Berg, Michel J., Bergey, Gregory K. , Boggs, Jane , Cash, Sydney S. , Cole, Andrew J. , Duchowny, Michael , Duckrow, Robert B., Eisenschenk, Stephan, Fessler, A. James, Fountain, Nathan B. , Geller, Eric B., Gwinn, Ryder P. , Heck, Christianne, Herekar, Aamr A., Hirsch, Lawrence J. , King‐Stephens, David , Labar, Douglas, Marsh, W. Richard , Meador, Kimford J. , Miller, Ian , Mizrahi, Eli M., Murro, Anthony M., Nair, Dileep , Olejniczak, Piotr W., Park, Yong D., Rutecki, Paul , Salanova, Vicenta , Sheth, Raj D. , Skidmore, Christopher , Spencer, David , Srinivasan, Shraddha, Tatum, William O. , Ness, Paul Van, Vossler, David G. , Wharen, Robert E. , Yoshor, Daniel , Zimmerman, Richard S. , Skarpaas, Tara L. , Morrell, Martha J. , Noe, Katherine H. , Edwards, Jonathan C. W. , Goldman, Alica M. , Goodman, Robert , Gross, Robert E. , Smith, Michael C. F. , Worrell, Gregory A. , Cole, Andrew J , Fountain, Nathan , Hirsch, Lawrence J , Meador, Kimford J , Jobst, Barbara , Nair, Dileep R , Skidmore, Christopher , Morrell, Martha J

Mayo Clinic

Epilepsia | April 7, 2017 | Volume: 58 | Issue: 6 | Pages: 1005-1014

10.1111/epi.13739 | PMID 28387951 Get It

SummaryObjectiveEvaluate the seizure‐reduction response and safety of brain‐responsive stimulation in adults with medically intractable partial‐onset seizures of neocortical origin.MethodsPatients with partial seizures of neocortical origin were identified from prospective clinical trials of a brain‐responsive neurostimulator (RNS System, NeuroPace). The seizure reduction over years 2–6 postimplantation was calculated by assessing the seizure frequency compared to a preimplantation baseline. Safety was assessed based on reported adverse events. Additional analyses considered safety and seizure reduction according to lobe and functional area (e.g., eloquent cortex) of seizure onset.ResultsThere were 126 patients with seizures of neocortical onset. The average follow‐up was 6.1 implant years. The median percent seizure reduction was 70% in patients with frontal and parietal seizure onsets, 58% in those with temporal neocortical onsets, and 51% in those with multilobar onsets (last observation carried forward [LOCF] analysis). Twenty‐six percent of patients experienced at least one seizure‐free period of 6 months or longer and 14% experienced at least one seizure‐free period of 1 year or longer. Patients with lesions on magnetic resonance imaging (MRI; 77% reduction, LOCF) and those with normal MRI findings (45% reduction, LOCF) benefitted, although the treatment response was more robust in patients with an MRI lesion (p = 0.02, generalized estimating equation [GEE]). There were no differences in the seizure reduction in patients with and without prior epilepsy surgery or vagus nerve stimulation. Stimulation parameters used for treatment did not cause acute or chronic neurologic deficits, even in eloquent cortical areas. The rates of infection (0.017 per patient implant year) and perioperative hemorrhage (0.8%) were not greater than with other neurostimulation devices.SignificanceBrain‐responsive stimulation represents a safe and effective treatment option for patients with medically intractable epilepsy, including adults with seizures of neocortical onset, and those with onsets from eloquent cortex.
Transscrotal Near Infrared Spectroscopy as a Diagnostic Test for Testis Torsion in Pediatric Acute Scrotum: A Prospective Comparison to Gold Standard Diagnostic Test Study
Schlomer, Bruce J., Keays, Mélise , Grimsby, Gwen M. , Granberg, Candace F. , DaJusta, Daniel , Menon, Vani S. , Ostrov, Lauren , Sheth, Kunj , Hill, Martinez, Sanchez, Emma, Harrison, Clanton B., Jacobs, Micah A. , Huang, Rong , Burgu, Berk , Hennes, Halim , Baker, Linda A.

Mayo Clinic

Journal of Urology | April 6, 2017 | Volume: 198 | Issue: 3 | Pages: 694-701

10.1016/j.juro.2017.03.134 | PMID 28392394 Get It

Endovascular Embolization by Transcatheter Delivery of Particles: Past, Present, and Future
Sheth, Rahul A. , Sabir, Sharjeel , Avery, Reginald K. , Khademhosseini, Ali, Öklü, Rahmi , Krishnamurthy, Savitri , Zhang, Yu Shrike , Oklu, Rahmi

Mayo Clinic

Journal of Functional Biomaterials | April 3, 2017 | Volume: 8 | Issue: 2 | Pages: 12

10.3390/jfb8020012 | PMID 28368345 Get It

Minimally invasive techniques to occlude flow within blood vessels, initially pioneered in the 1970s with autologous materials and subsequently advanced with increasingly sophisticated engineered biomaterials, are routinely performed for a variety of medical conditions. Contemporary interventional radiologists have at their disposal a wide armamentarium of occlusive agents to treat a range of disease processes through a small incision in the skin. In this review, we provide a historical perspective on endovascular embolization tools, summarize the current state-of-the-art, and highlight burgeoning technologies that promise to advance the field in the near future.